Nov 11, 2024
STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
Jun 17, 2024
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Jun 03, 2024
STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
May 24, 2024
STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
Feb 22, 2024
STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress
Oct 22, 2020
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
Jul 28, 2020
STORM Therapeutics to Present at Two Scientific Conferences in July 2020
Jun 23, 2020
STORM Therapeutics Appoints Dr. Josefin-Beate Holz as Chief Medical Officer
Feb 17, 2020
Analysis of RNA Sequences and Modifications by Mass Spectrometry Published in Nature Communications
Dec 09, 2019
STORM Therapeutics' Collaborator Awarded ASH-BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition
Aug 20, 2019
STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK
Jun 27, 2019
STORM Therapeutics Appoints Dr John Haurum to the Board of Directors
May 20, 2019
STORM Therapeutics Extends Series A to GBP 30M (USD 38.43M) with New Investor, Seroba Life Sciences
Jan 29, 2018
STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
Jan 08, 2018
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
Nov 27, 2017
STORM Therapeutics Announces Publication in Nature on RNA Epigenetics by Founder Professor Tony Kouzarides
Nov 06, 2017
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research